Pictorial review on abdominal applications of ferumoxytol in MR imaging
Though gadolinium-based contrast agents are the most widely used contrast media in MR for clinical use, problems with nephrogenic systemic fibrosis and tissue deposition render their safety debatable, at least in a selected patient population. Ferumoxytol has the potential to be used as an alternate contrast medium for various clinical applications across multiple organs. It has prolonged intravascular signal and delayed intracellular macrophage uptake which are unique properties compared to gadolinium-based agents. This pictorial review aims to review the current and potential clinical applications of ferumoxytol as a contrast agent in abdominal MR imaging.
KeywordsMagnetic resonance imaging Ferumoxytol USPIO Contrast media
There is no source of funding for this review article.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings [Internet]. [cited 2018 Jul 28]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm
- 3.Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2010 Jan;30(1):15–35.CrossRefGoogle Scholar
- 4.Auerbach M, Chertow GM, Rosner M. Ferumoxytol for the treatment of iron deficiency anemia. Expert Rev Hematol. 2018 Sep 6;0(ja):null.Google Scholar
- 8.Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010 May;85(5):315–9.Google Scholar
- 12.Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014 Jun;89(6):646–50.CrossRefGoogle Scholar
- 13.Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol) [Internet]. [cited 2018 Jul 28]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm440138.htm
- 14.Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery. 2007 Apr;60(4):601–11; discussion 611-612.Google Scholar
- 19.Knobloch G, Colgan T, Wiens CN, Wang X, Schubert T, Hernando D, et al. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T. Invest Radiol. 2018 May;53(5):257–63.Google Scholar
- 28.Ford DC, Dahl NV, Strauss WE, Barish CF, Hetzel DJ, Bernard K, et al. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clin Exp Gastroenterol. 2016 Jul 11;9:151–62.Google Scholar
- 29.Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014 Jun;89(6):646–50.CrossRefGoogle Scholar
- 30.Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn’s Disease Activity and Treatment Response [Internet]. Gastroenterology Research and Practice. 2016 [cited 2018 Jun 30]. Available from: https://www.hindawi.com/journals/grp/2016/8168695/
- 35.Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-del Castillo C, Harisinghani MG. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int J Nanomedicine. 2014;9:1891–6.CrossRefGoogle Scholar
- 39.Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol. 2002 Apr;23(4):649–56.Google Scholar
- 43.Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol. 2005 Sep;174(3):923–7; discussion 927.Google Scholar
- 47.Nguyen K-L, Moriarty JM, Plotnik AN, Aksoy O, Yoshida T, Shemin RJ, et al. Ferumoxytol-enhanced MR Angiography for Vascular Access Mapping before Transcatheter Aortic Valve Replacement in Patients with Renal Impairment: A Step Toward Patient-specific Care. Radiology. 2018;286(1):326–37.CrossRefGoogle Scholar
- 49.MA3RS Study Investigators. Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture, and Need for Surgical Repair. Circulation. 2017 Aug 29;136(9):787–97.Google Scholar
- 58.Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol. 93(5):683–90.Google Scholar